Update on Appropriate Use Criteria for Amyloid PET Imaging: Dementia Experts, Mild Cognitive Impairment, and Education

Journal of Nuclear Medicine

Keith A. Johnson¹  Peter Herscovitch¹  Saima Hedrick¹  Kevin J. Donohoe¹  Maria C. Carrillo¹  Norman L. Foster¹  Jason H. Karlawish¹  Satoshi Minoshima¹  Virginia Pappas¹  Nicolaas I. Bohnen¹  Dean M. Hartley¹  Christopher C. Rowe¹ 

关键词: amyloid PET;    dementia;    Alzheimer disease;   

DOI  :  10.2967/jnumed.113.127068

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging previously published appropriate use criteria for amyloid PET as an important tool for increasing the certainty of a diagnosis of Alzheimer disease in specific patient populations. Here, the task force further clarifies and expands 3 topics discussed in the original paper: first, defining dementia experts and their use of proper documentation to demonstrate the medical necessity of an amyloid PET scan; second, identifying a specific subset of individuals with mild cognitive impairment for whom an amyloid PET scan is appropriate; and finally, developing educational programs to increase awareness of the amyloid PET appropriate use criteria and providing instructions on how this test should be used in the clinical decision-making process.

【 授权许可】

Unknown